Nucleic acids from rare cells circulating in the bloodstream, such as circulating tumor cells (CTC), circulating endothelial cells (CEC), circulating fetal cells (CFC) and others, present great opportunities for non-invasive cancer screening, diagnostics, prognosis, prospective non-invasive companion diagnostics and prenatal diagnostics.
The purpose of this questionnaire is to understand your needs for current and future rare-cell collection and enrichment that can be combined with non-invasive molecular assays in research and diagnostics areas.
Your feedback is invaluable information for our innovation efforts to meet your specific workflow demands.
Sincerely,
QIAGEN Customer Care Team
